2024-01-012024-12-312024-12-31false09930790Sahli Medical Limited2025-07-0986220falseiso4217:GBPxbrli:pure099307902023-12-31099307902024-12-31099307902024-01-012024-12-31099307902022-12-31099307902023-12-31099307902023-01-012023-12-3109930790bus:SmallEntities2024-01-012024-12-3109930790bus:AuditExempt-NoAccountantsReport2024-01-012024-12-3109930790bus:FullAccounts2024-01-012024-12-3109930790bus:PrivateLimitedCompanyLtd2024-01-012024-12-3109930790core:WithinOneYear2024-12-3109930790core:AfterOneYear2024-12-3109930790core:WithinOneYear2023-12-3109930790core:AfterOneYear2023-12-3109930790core:ShareCapital2024-12-3109930790core:SharePremium2024-12-3109930790core:RevaluationReserve2024-12-3109930790core:OtherReservesSubtotal2024-12-3109930790core:RetainedEarningsAccumulatedLosses2024-12-3109930790core:ShareCapital2023-12-3109930790core:SharePremium2023-12-3109930790core:RevaluationReserve2023-12-3109930790core:OtherReservesSubtotal2023-12-3109930790core:RetainedEarningsAccumulatedLosses2023-12-3109930790core:LandBuildings2024-12-3109930790core:PlantMachinery2024-12-3109930790core:Vehicles2024-12-3109930790core:FurnitureFittings2024-12-3109930790core:OfficeEquipment2024-12-3109930790core:NetGoodwill2024-12-3109930790core:IntangibleAssetsOtherThanGoodwill2024-12-3109930790core:ListedExchangeTraded2024-12-3109930790core:UnlistedNon-exchangeTraded2024-12-3109930790core:LandBuildings2023-12-3109930790core:PlantMachinery2023-12-3109930790core:Vehicles2023-12-3109930790core:FurnitureFittings2023-12-3109930790core:OfficeEquipment2023-12-3109930790core:NetGoodwill2023-12-3109930790core:IntangibleAssetsOtherThanGoodwill2023-12-3109930790core:ListedExchangeTraded2023-12-3109930790core:UnlistedNon-exchangeTraded2023-12-3109930790core:LandBuildings2024-01-012024-12-3109930790core:PlantMachinery2024-01-012024-12-3109930790core:Vehicles2024-01-012024-12-3109930790core:FurnitureFittings2024-01-012024-12-3109930790core:OfficeEquipment2024-01-012024-12-3109930790core:NetGoodwill2024-01-012024-12-3109930790core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3109930790core:ListedExchangeTraded2024-01-012024-12-3109930790core:UnlistedNon-exchangeTraded2024-01-012024-12-3109930790core:MoreThanFiveYears2024-01-012024-12-3109930790core:Non-currentFinancialInstruments2024-12-3109930790core:Non-currentFinancialInstruments2023-12-3109930790dpl:CostSales2024-01-012024-12-3109930790dpl:DistributionCosts2024-01-012024-12-3109930790core:LandBuildings2024-01-012024-12-3109930790core:PlantMachinery2024-01-012024-12-3109930790core:Vehicles2024-01-012024-12-3109930790core:FurnitureFittings2024-01-012024-12-3109930790core:OfficeEquipment2024-01-012024-12-3109930790dpl:AdministrativeExpenses2024-01-012024-12-3109930790core:NetGoodwill2024-01-012024-12-3109930790core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3109930790dpl:GroupUndertakings2024-01-012024-12-3109930790dpl:ParticipatingInterests2024-01-012024-12-3109930790dpl:GroupUndertakingscore:ListedExchangeTraded2024-01-012024-12-3109930790core:ListedExchangeTraded2024-01-012024-12-3109930790dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-01-012024-12-3109930790core:UnlistedNon-exchangeTraded2024-01-012024-12-3109930790dpl:CostSales2023-01-012023-12-3109930790dpl:DistributionCosts2023-01-012023-12-3109930790core:LandBuildings2023-01-012023-12-3109930790core:PlantMachinery2023-01-012023-12-3109930790core:Vehicles2023-01-012023-12-3109930790core:FurnitureFittings2023-01-012023-12-3109930790core:OfficeEquipment2023-01-012023-12-3109930790dpl:AdministrativeExpenses2023-01-012023-12-3109930790core:NetGoodwill2023-01-012023-12-3109930790core:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-3109930790dpl:GroupUndertakings2023-01-012023-12-3109930790dpl:ParticipatingInterests2023-01-012023-12-3109930790dpl:GroupUndertakingscore:ListedExchangeTraded2023-01-012023-12-3109930790core:ListedExchangeTraded2023-01-012023-12-3109930790dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-01-012023-12-3109930790core:UnlistedNon-exchangeTraded2023-01-012023-12-3109930790core:NetGoodwill2024-12-3109930790core:IntangibleAssetsOtherThanGoodwill2024-12-3109930790core:LandBuildings2024-12-3109930790core:PlantMachinery2024-12-3109930790core:Vehicles2024-12-3109930790core:FurnitureFittings2024-12-3109930790core:OfficeEquipment2024-12-3109930790core:AfterOneYear2024-12-3109930790core:WithinOneYear2024-12-3109930790core:ListedExchangeTraded2024-12-3109930790core:UnlistedNon-exchangeTraded2024-12-3109930790core:ShareCapital2024-12-3109930790core:SharePremium2024-12-3109930790core:RevaluationReserve2024-12-3109930790core:OtherReservesSubtotal2024-12-3109930790core:RetainedEarningsAccumulatedLosses2024-12-3109930790core:NetGoodwill2023-12-3109930790core:IntangibleAssetsOtherThanGoodwill2023-12-3109930790core:LandBuildings2023-12-3109930790core:PlantMachinery2023-12-3109930790core:Vehicles2023-12-3109930790core:FurnitureFittings2023-12-3109930790core:OfficeEquipment2023-12-3109930790core:AfterOneYear2023-12-3109930790core:WithinOneYear2023-12-3109930790core:ListedExchangeTraded2023-12-3109930790core:UnlistedNon-exchangeTraded2023-12-3109930790core:ShareCapital2023-12-3109930790core:SharePremium2023-12-3109930790core:RevaluationReserve2023-12-3109930790core:OtherReservesSubtotal2023-12-3109930790core:RetainedEarningsAccumulatedLosses2023-12-3109930790core:NetGoodwill2022-12-3109930790core:IntangibleAssetsOtherThanGoodwill2022-12-3109930790core:LandBuildings2022-12-3109930790core:PlantMachinery2022-12-3109930790core:Vehicles2022-12-3109930790core:FurnitureFittings2022-12-3109930790core:OfficeEquipment2022-12-3109930790core:AfterOneYear2022-12-3109930790core:WithinOneYear2022-12-3109930790core:ListedExchangeTraded2022-12-3109930790core:UnlistedNon-exchangeTraded2022-12-3109930790core:ShareCapital2022-12-3109930790core:SharePremium2022-12-3109930790core:RevaluationReserve2022-12-3109930790core:OtherReservesSubtotal2022-12-3109930790core:RetainedEarningsAccumulatedLosses2022-12-3109930790core:AfterOneYear2024-01-012024-12-3109930790core:WithinOneYear2024-01-012024-12-3109930790core:Non-currentFinancialInstrumentscore:CostValuation2024-01-012024-12-3109930790core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-01-012024-12-3109930790core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-01-012024-12-3109930790core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-01-012024-12-3109930790core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-01-012024-12-3109930790core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-01-012024-12-3109930790core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-01-012024-12-3109930790core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-01-012024-12-3109930790core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-01-012024-12-3109930790core:Non-currentFinancialInstrumentscore:CostValuation2024-12-3109930790core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-12-3109930790core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-12-3109930790core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-12-3109930790core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-12-3109930790core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-12-3109930790core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-12-3109930790core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-12-3109930790core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-12-3109930790core:Non-currentFinancialInstrumentscore:CostValuation2023-12-3109930790core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-12-3109930790core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-12-3109930790core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-12-3109930790core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-12-3109930790core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-12-3109930790core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-12-3109930790core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-12-3109930790core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-12-3109930790bus:Director12024-01-012024-12-31

Sahli Medical Limited

Registered Number
09930790
(England and Wales)

Unaudited Financial Statements for the Year ended
31 December 2024

Sahli Medical Limited
Company Information
for the year from 1 January 2024 to 31 December 2024

Director

Dr Alaa Hassan

Company Secretary

Soha Khalifa

Registered Address

7 Parkland Avenue
Carlisle
CA1 3GN

Registered Number

09930790 (England and Wales)
Sahli Medical Limited
Statement of Financial Position
31 December 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets3737867
737867
Current assets
Debtors536,8053,600
Cash at bank and on hand196145,479
37,001149,079
Creditors amounts falling due within one year6(600)(105,633)
Net current assets (liabilities)36,40143,446
Total assets less current liabilities37,13844,313
Net assets37,13844,313
Capital and reserves
Called up share capital55
Profit and loss account37,13344,308
Shareholders' funds37,13844,313
The financial statements were approved and authorised for issue by the Director on 9 July 2025, and are signed on its behalf by:
Dr Alaa Hassan
Director
Registered Company No. 09930790
Sahli Medical Limited
Notes to the Financial Statements
for the year ended 31 December 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Judgements and key sources of estimation uncertainty
Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. There are no key assumptions and other sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Current taxation
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)
Plant and machinery15
Trade and other debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are disclosed separately. For the purpose of the cash flow statement, bank overdrafts form an integral part of the company's cash management and are included as a component of cash and cash equivalents.
Trade and other creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
2.Average number of employees

20242023
Average number of employees during the year33
3.Tangible fixed assets

Plant & machinery

Total

££
Cost or valuation
At 01 January 242,6082,608
At 31 December 242,6082,608
Depreciation and impairment
At 01 January 241,7411,741
Charge for year130130
At 31 December 241,8711,871
Net book value
At 31 December 24737737
At 31 December 23867867
4.Impairment of tangible fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.
5.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables-3,600
Other debtors36,805-
Total36,8053,600
6.Creditors: amounts due within one year

2024

2023

££
Taxation and social security-3,889
Other creditors-101,144
Accrued liabilities and deferred income600600
Total600105,633
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
7.Directors advances, credits and guarantees
Included within other debtors falling due within one year is £35,740 being the amount owed by the director. Net amounts advanced during the year were £136,884. These amounts were both repaid within nine months of the financial year. The loans were charged the official rate of interest were applicable and were repayable on demand.